The Lung Cancer Research Foundation (LCRF) announces today a new funding mechanism: the 2025 LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The Request for ...

The Lung Cancer Research Foundation (LCRF) announces today a new research collaboration with Boehringer Ingelheim creating two funding mechanisms designed to address HER2 mutations in lung cancer: a ...

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP ...

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

Dr Amit Rauthan, Head, Department and Consultant, Medical Oncology and Hemato-Oncology, Manipal Hospital, explains how the advancements in oncology are offering hope by transforming cancer into a more ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Cancer patients found to have specific gene mutations or other biomarkers are being matched to precision treatments not ...

In contrast, when using the traditional race-adjusted creatinine-based equation (eGFRcr-ASR), the HR was 2.8 (95% CI, 1.6–4.9 ...

Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial. The findings were ...

EGFR inhibitors such as Erbitux and Gilotrif show potential in laboratory and mouse studies in treating melanoma with a ...

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations. Improving survival and ...